A wide range of molecular imaging techniques are available that can provide complementary information to conventional, anatomical imaging for the evaluation of known or suspected bone and soft tissue sarcomas. In particular, positron emission tomography (PET), particularly in the form of hybrid PET/CT technology, offers many potential advantages over current imaging approaches by delineating not only the extent of disease but also the biological heterogeneity that can exist both between and within sarcomas. This review discusses the clinical situations where nuclear medicine techniques can aid in the management of patients with sarcoma. These include biopsy guidance, whole body staging, therapeutic response assessment and evaluation of resi...
A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resi...
The present status of cancer molecular imaging (MI) with nuclear medicine techniques is reviewed, hi...
Item does not contain fulltextTargeted treatment has substantially changed the field of oncology. Co...
Positron emission tomography (PET) with the fluorine-18-labeled glucose analog FDG is a technique th...
According to the preliminary data published so far, PET seems to be valuable method for evaluating p...
Sarcoma originated in bone or soft tissue is relatively rare disease. PET have been used in sarcoma...
Background: Sarcomas represent a significant diagnostic and therapeutic challenge that requires tech...
Contains fulltext : 71333.pdf (publisher's version ) (Open Access)A correct histol...
Sarcomas are often characterised by significant histopathologic heterogeneity, both between and with...
Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) is the imaging ...
Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is a new whole-...
Knowledge of imaging findings related to therapy administered to patients with sarcoma is pivotal in...
PET with F-18-fluoro-2-deoxy-D-glucose (FDG) was used to study soft-tissue lesions, The goals of the...
FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases
Nuclear medicine allows imaging of (patho) physiological processes within the body and contributes i...
A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resi...
The present status of cancer molecular imaging (MI) with nuclear medicine techniques is reviewed, hi...
Item does not contain fulltextTargeted treatment has substantially changed the field of oncology. Co...
Positron emission tomography (PET) with the fluorine-18-labeled glucose analog FDG is a technique th...
According to the preliminary data published so far, PET seems to be valuable method for evaluating p...
Sarcoma originated in bone or soft tissue is relatively rare disease. PET have been used in sarcoma...
Background: Sarcomas represent a significant diagnostic and therapeutic challenge that requires tech...
Contains fulltext : 71333.pdf (publisher's version ) (Open Access)A correct histol...
Sarcomas are often characterised by significant histopathologic heterogeneity, both between and with...
Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) is the imaging ...
Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is a new whole-...
Knowledge of imaging findings related to therapy administered to patients with sarcoma is pivotal in...
PET with F-18-fluoro-2-deoxy-D-glucose (FDG) was used to study soft-tissue lesions, The goals of the...
FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases
Nuclear medicine allows imaging of (patho) physiological processes within the body and contributes i...
A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resi...
The present status of cancer molecular imaging (MI) with nuclear medicine techniques is reviewed, hi...
Item does not contain fulltextTargeted treatment has substantially changed the field of oncology. Co...